Viewing Study NCT06543914



Ignite Creation Date: 2024-10-26 @ 3:37 PM
Last Modification Date: 2024-10-26 @ 3:37 PM
Study NCT ID: NCT06543914
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-08-06

Brief Title: Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Sponsor: None
Organization: None

Study Overview

Official Title: A ProspeCtive ObseRvatioNal Study of Atogepant Effectiveness in Routine Clinical Practice
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CORNERSTONE
Brief Summary: Migraine is a neurological disease characterized by moderate or severe headache associated with nausea vomiting andor sensitivity to light and sound This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting

Atogepant is an approved drug for preventive treatment of migraine in adults Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world

Participants will receive atogepant oral tablets as prescribed per standard clinical practice and will be followed for 2 years

There is expected to be no additional burden for participants in this trial Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None